DACOGEN: Uses, Dosage & Side Effects
A hypomethylating agent (epigenetic therapy) used to treat adult patients with newly diagnosed acute myeloid leukemia (AML) who are not candidates for standard intensive chemotherapy
DACOGEN (decitabine) is a hypomethylating agent used to treat adults with newly diagnosed acute myeloid leukemia (AML) who are not eligible for standard intensive induction chemotherapy. As an epigenetic therapy, decitabine works by inhibiting DNA methyltransferase, reversing the abnormal gene silencing that drives leukemia cell growth. DACOGEN is administered as an intravenous infusion in a hospital setting and requires a prescription. It represents an important treatment option for elderly AML patients and those with significant comorbidities who cannot tolerate aggressive chemotherapy regimens, offering the possibility of improved blood counts and disease control with a more manageable side effect profile.
Quick Facts: DACOGEN
Key Takeaways
- DACOGEN (decitabine) is an epigenetic therapy approved for adult AML patients who are not candidates for intensive chemotherapy, typically elderly patients or those with significant comorbidities.
- It is given as a 1-hour intravenous infusion daily for 5 consecutive days in each 4-week treatment cycle, with a recommended minimum of 4 cycles to assess response.
- The most common side effects are low blood cell counts (myelosuppression), infections, bleeding, fever, nausea, and abnormal liver function – regular blood monitoring is essential.
- DACOGEN must not be used during pregnancy or breastfeeding; both men and women must use effective contraception during and after treatment.
- Differentiation syndrome is a rare but serious immune reaction that requires immediate medical attention if symptoms such as fever, breathing difficulties, or rapid weight gain occur.
What Is DACOGEN and What Is It Used For?
DACOGEN contains the active substance decitabine, a nucleoside analogue that belongs to a class of medications known as hypomethylating agents (HMAs). These drugs represent a relatively newer approach to cancer treatment that works at the epigenetic level, meaning they alter how genes are expressed rather than directly damaging DNA like traditional chemotherapy agents. This mechanism makes DACOGEN particularly valuable for patients who cannot tolerate the harsh side effects of conventional intensive chemotherapy.
Acute myeloid leukemia (AML) is a type of cancer that affects the blood and bone marrow. In AML, the bone marrow produces abnormal white blood cells (called myeloid blasts) that accumulate in the blood and bone marrow, crowding out healthy blood cells. This leads to a shortage of normal red blood cells (causing anemia and fatigue), white blood cells (increasing infection risk), and platelets (causing bleeding and bruising). AML is the most common type of acute leukemia in adults, with incidence increasing significantly with age – the median age at diagnosis is approximately 68 years.
DACOGEN is specifically approved for the treatment of adults aged 65 years and older with newly diagnosed de novo or secondary AML who are not candidates for standard induction chemotherapy. This includes patients who are elderly, have significant comorbidities (such as heart disease, kidney problems, or poor overall performance status), or have other factors that would make intensive chemotherapy too risky. The European Medicines Agency (EMA) granted marketing authorization for DACOGEN in 2012 based on clinical trial data demonstrating its efficacy in this patient population.
How Does DACOGEN Work?
DACOGEN works through a unique mechanism known as DNA hypomethylation. In cancer cells, certain genes that normally suppress tumor growth become silenced through a process called DNA methylation – essentially, chemical tags (methyl groups) are added to the DNA, preventing these protective genes from being activated. This aberrant methylation is a hallmark of many cancers, including AML.
When DACOGEN is administered, decitabine is incorporated into the DNA of dividing cells during DNA replication. Once embedded in the DNA, decitabine irreversibly binds to and inhibits DNA methyltransferase (DNMT), the enzyme responsible for adding methyl groups to DNA. By blocking this enzyme, DACOGEN causes the DNA to become hypomethylated, effectively removing the silencing marks from tumor suppressor genes. This allows these previously silenced genes to become active again, restoring normal cellular processes including differentiation (where immature blast cells mature into functional blood cells) and apoptosis (programmed cell death of abnormal cells).
At the low doses used clinically (20 mg/m²), the primary mechanism of action is this epigenetic reprogramming rather than direct cytotoxicity. This is an important distinction from traditional chemotherapy, which primarily works by causing DNA damage and killing rapidly dividing cells. The epigenetic approach means that DACOGEN can have therapeutic effects at lower, better-tolerated doses, which is particularly advantageous for elderly and frail patients. However, the full therapeutic benefit may take several treatment cycles to manifest, as the epigenetic changes need time to propagate through the leukemia cell population.
What Should You Know Before Receiving DACOGEN?
Contraindications
DACOGEN must not be used in certain situations where the risks clearly outweigh the potential benefits. Understanding these contraindications is essential for patient safety. You should not receive DACOGEN if you have a known allergy (hypersensitivity) to decitabine or any of the other ingredients in the formulation, including potassium dihydrogen phosphate, sodium hydroxide, or hydrochloric acid. Allergic reactions can range from mild skin rash to severe anaphylaxis, so any history of previous hypersensitivity to this drug or its components must be communicated to your healthcare team.
DACOGEN is absolutely contraindicated during breastfeeding. It is not known whether decitabine or its metabolites are excreted in human breast milk, but given the drug's mechanism of action and potential for serious adverse effects in nursing infants, breastfeeding must be discontinued before starting treatment and must not be resumed during therapy.
Do not use DACOGEN if you are breastfeeding or if you have a known allergy to decitabine. Tell your doctor immediately if you become pregnant during treatment. DACOGEN can cause serious harm to an unborn baby.
Warnings and Precautions
Before and during treatment with DACOGEN, your healthcare team will need to carefully monitor your health. Talk to your doctor, pharmacist, or nurse before receiving DACOGEN if you have any of the following conditions:
- Low blood cell counts: If you already have low levels of platelets (thrombocytopenia), red blood cells (anemia), or white blood cells (neutropenia), DACOGEN will likely worsen these conditions initially. Your doctor will perform regular blood tests and may need to provide supportive care such as blood transfusions or growth factor injections.
- Active infection: Since DACOGEN suppresses the immune system, any existing infection should be treated and ideally resolved before starting therapy. During treatment, you will be at increased risk of infections, including opportunistic infections.
- Liver disease: Abnormal liver function is a common side effect of DACOGEN. If you have pre-existing liver problems, your doctor will need to monitor liver function tests more frequently and may need to adjust treatment accordingly.
- Severe kidney disease: Although decitabine is not primarily eliminated through the kidneys, severe renal impairment may affect drug clearance and increase the risk of adverse effects. Your doctor will assess kidney function before and during treatment.
- Heart disease: Patients with pre-existing cardiovascular conditions should be monitored carefully, as DACOGEN treatment can cause complications that may worsen cardiac function.
DACOGEN can cause a serious immune reaction called differentiation syndrome. This occurs when leukemia cells rapidly differentiate (mature) in response to treatment, releasing inflammatory substances. Symptoms include fever, cough, breathing difficulties, rash, decreased urine output, low blood pressure, swelling in the arms or legs, and rapid weight gain. If you experience any of these symptoms, contact your healthcare team immediately, as differentiation syndrome requires prompt treatment.
You will have regular blood tests before starting treatment and at the beginning of each treatment cycle. These tests check that your blood cell counts are adequate, and that your liver and kidneys are functioning properly. Ask your doctor about your test results.
Children and Adolescents
DACOGEN should not be used in children or adolescents under 18 years of age. The safety and efficacy of decitabine have not been established in the pediatric population for the treatment of AML. Pediatric AML is typically treated with different therapeutic approaches that have been specifically studied and validated in younger patients.
Pregnancy and Breastfeeding
DACOGEN poses significant risks to reproductive health and must be approached with extreme caution in patients of childbearing potential. The drug is expected to cause serious birth defects based on its mechanism of action, which involves altering DNA methylation patterns critical for embryonic development.
Women of childbearing potential: If you are a woman who could become pregnant, your doctor will require a pregnancy test before starting treatment with DACOGEN. You must use highly effective contraception during treatment and for at least 6 months after the last dose. If you discover you are pregnant during treatment, tell your doctor immediately – the potential risks to the fetus must be carefully evaluated.
Men: Male patients should not father a child during treatment with DACOGEN. Effective contraception must be used during treatment and for at least 3 months after the last dose. Decitabine may affect sperm quality and male fertility. If you wish to have children in the future, discuss sperm cryopreservation (freezing) with your doctor before starting treatment.
Breastfeeding: You must not breastfeed during treatment with DACOGEN. It is unknown whether decitabine passes into breast milk, but given the drug's mechanism of action, exposure through breast milk could harm the nursing infant.
Driving and Using Machines
DACOGEN treatment can cause fatigue and weakness, which are very common side effects. If you experience these symptoms, you should not drive or operate machinery until you feel well enough to do so safely. Your ability to react may be impaired, so exercise caution with any activities requiring alertness.
Important Information About Excipients
This medicine contains potassium and sodium. Each vial contains 0.5 mmol potassium. After reconstitution, the prepared solution contains less than 1 mmol (39 mg) potassium per dose, meaning it is essentially potassium-free. Each vial also contains 0.29 mmol (6.67 mg) sodium. After reconstitution, the solution contains 13.8–138 mg sodium per dose, equivalent to 0.7–7% of the WHO recommended maximum daily intake of sodium for adults. Inform your doctor if you are on a low-sodium diet.
How Does DACOGEN Interact with Other Drugs?
Drug interactions are an important consideration when receiving DACOGEN treatment. Decitabine's immunosuppressive effects and its unique mechanism of action mean that certain combinations may either reduce its effectiveness or increase the risk of serious adverse effects. No formal clinical drug interaction studies have been conducted with DACOGEN; however, based on its pharmacological properties and clinical experience, several types of interactions are recognized.
Before starting treatment, you must tell your doctor about all medicines you are currently taking, have recently taken, or might take. This includes prescription medications, over-the-counter drugs, vitamins, and herbal or natural remedies. Your healthcare team will assess potential interactions and adjust your treatment plan accordingly.
| Interacting Drug/Class | Type | Clinical Significance |
|---|---|---|
| Live vaccines (e.g., MMR, varicella, BCG) | Contraindicated | Risk of disseminated vaccine infection due to immunosuppression. Avoid live vaccines during treatment and for a period after. Inactivated vaccines may have reduced efficacy. |
| Other immunosuppressants | Major | Additive immunosuppression increases infection risk. Careful monitoring required if co-administered with other immunosuppressive agents. |
| Cytarabine (Ara-C) | Moderate | Both are nucleoside analogues that incorporate into DNA. Potential for pharmacodynamic interaction; sequence and timing of administration may affect efficacy. |
| Myelosuppressive agents | Major | Additive bone marrow suppression. Combined use with other myelotoxic drugs increases risk of severe cytopenias, infections, and bleeding. |
| Anticoagulants (e.g., warfarin, heparin) | Moderate | DACOGEN-induced thrombocytopenia increases bleeding risk. Dose adjustments and closer monitoring of coagulation parameters may be needed. |
| CYP enzyme substrates | Minor | Decitabine is primarily inactivated by cytidine deaminase, not CYP enzymes. Clinically significant CYP-mediated interactions are not expected, but caution is advised with narrow therapeutic index drugs. |
Key Interaction Considerations
The most clinically important interactions with DACOGEN relate to its immunosuppressive effects. Because decitabine suppresses the bone marrow and reduces immune function, live vaccines must be avoided during treatment. Vaccination with live attenuated organisms could lead to uncontrolled, disseminated infection in an immunocompromised patient. If vaccination is necessary, only inactivated vaccines should be used, although the immune response may be suboptimal.
Patients receiving anticoagulant therapy require particularly careful monitoring when on DACOGEN, as the drug frequently causes thrombocytopenia (low platelet counts). The combination of reduced platelet function and anticoagulation therapy significantly increases the risk of bleeding complications. Your doctor may need to adjust anticoagulant doses or temporarily withhold them during periods of severe thrombocytopenia.
Concomitant use of other drugs that suppress bone marrow function (such as certain antibiotics, antifungal agents, or other chemotherapy drugs) should be carefully managed, as the additive myelosuppressive effects can lead to dangerously low blood cell counts. Your healthcare team will monitor your blood counts closely and may adjust the timing or doses of concurrent medications.
What Is the Correct Dosage of DACOGEN?
DACOGEN will be administered by a doctor or nurse who is trained in giving this type of medication. The dose is individualized based on your body surface area (calculated from your height and weight) and your response to treatment. Understanding the dosing regimen helps you prepare for what to expect during your treatment course.
Adults
Standard Dosing Regimen
Dose: 20 mg/m² body surface area
Route: Intravenous infusion over 1 hour
Schedule: Once daily for 5 consecutive days
Cycle length: 4 weeks (5 days of treatment followed by 23 days without)
Minimum treatment: 4 cycles recommended before assessing response
Duration: Treatment continues as long as the patient benefits or until unacceptable toxicity
The standard DACOGEN regimen consists of a 5-day intravenous infusion schedule repeated every 4 weeks. Each treatment day, you will receive the infusion over approximately 1 hour. The 5 days of active treatment are followed by a 23-day rest period, during which your bone marrow has time to recover before the next cycle begins. This intermittent dosing schedule is designed to achieve optimal epigenetic effects while allowing hematologic recovery between cycles.
It is important to understand that DACOGEN may take several cycles to produce a clinical response. Unlike traditional chemotherapy, which often shows effects quickly, the epigenetic mechanism of decitabine means that therapeutic benefits may not become apparent until after 3 to 4 cycles of treatment. For this reason, a minimum of 4 treatment cycles is strongly recommended before assessing whether the drug is working. Some patients may not achieve their best response until after 6 or more cycles. Your doctor will regularly evaluate your response and may continue treatment for many months if you are benefiting from it.
| Patient Group | Dose | Schedule | Notes |
|---|---|---|---|
| Adults (≥18 years) | 20 mg/m²/day IV | Days 1–5, every 4 weeks | Minimum 4 cycles; continue if benefiting |
| Elderly (>65 years) | 20 mg/m²/day IV | Days 1–5, every 4 weeks | No dose adjustment for age alone; primary target population |
| Renal impairment | 20 mg/m²/day IV | Days 1–5, every 4 weeks | No formal dose adjustment; monitor closely |
| Hepatic impairment | 20 mg/m²/day IV | Days 1–5, every 4 weeks | No formal studies; monitor liver function |
| Children (<18 years) | Not recommended | N/A | Safety and efficacy not established in pediatric patients |
Dose Modifications
Your doctor may need to delay your treatment or modify the number of cycles based on how you respond and any side effects you experience. Common reasons for dose delays include prolonged low blood cell counts (cytopenias) that have not recovered sufficiently before the next planned cycle. If your bone marrow needs more time to recover between cycles, your doctor may extend the interval beyond 4 weeks. Dose reductions below 20 mg/m² are not typically recommended, as this may compromise the drug's epigenetic efficacy.
Missed Dose
If you miss an appointment for your DACOGEN infusion, you should contact your healthcare team as soon as possible to reschedule. It is important to adhere to the treatment schedule as closely as possible for the drug to work effectively. Your doctor will advise you on whether the missed dose should be made up or whether the treatment cycle should be adjusted accordingly.
Overdose
Since DACOGEN is administered by healthcare professionals in a controlled clinical setting, the risk of accidental overdose is very low. In the unlikely event that too much DACOGEN is given, your doctor will monitor you closely for side effects – particularly severe myelosuppression (very low blood cell counts) – and provide appropriate supportive treatment. There is no specific antidote for decitabine overdose; management is symptomatic and supportive.
How DACOGEN Is Prepared and Given
DACOGEN is supplied as a white to off-white powder that must be reconstituted and further diluted by a pharmacist or nurse before administration. The powder is reconstituted with sterile water for injections, then diluted in cold saline (0.9% sodium chloride) or glucose (5% dextrose) infusion solution. The prepared solution must be used within specific time frames to ensure stability and sterility. Healthcare professionals handling the drug should wear protective gloves and follow standard procedures for cytotoxic medications to avoid skin contact with the solution.
What Are the Side Effects of DACOGEN?
Like all medicines, DACOGEN can cause side effects, although not everyone experiences them. The side effects of decitabine are largely related to its mechanism of action on rapidly dividing cells, particularly in the bone marrow. Understanding potential side effects helps you recognize warning signs early and communicate effectively with your healthcare team.
- Fever: May indicate infection caused by low white blood cell counts (very common)
- Chest pain or shortness of breath (with or without fever/cough): May indicate pneumonia (very common), interstitial lung disease (frequency not known), or cardiomyopathy (uncommon)
- Bleeding: Including blood in stool, which may indicate gastrointestinal bleeding (common)
- Neurological changes: Difficulty moving, speaking, seeing, sudden severe headache, seizures, numbness or weakness – may indicate intracranial bleeding (common)
- Allergic reactions: Difficulty breathing, swollen lips, itching, or rash (common)
- Differentiation syndrome: Fever, cough, breathing difficulties, rash, decreased urine, low blood pressure, swollen limbs, rapid weight gain (frequency not known)
Side Effects by Frequency
Very Common
Affects more than 1 in 10 patients
- Urinary tract infection
- Other infections (bacterial, viral, or fungal) in any part of the body
- Bleeding or easy bruising (thrombocytopenia – low platelet count)
- Fatigue or paleness (anemia – low red blood cell count)
- High blood sugar levels (hyperglycemia)
- Headache
- Nosebleeds (epistaxis)
- Diarrhea
- Vomiting
- Nausea
- Fever (pyrexia)
- Abnormal liver function tests
Common
Affects up to 1 in 10 patients
- Bloodstream infection (sepsis) – may indicate low white blood cell count
- Sore or runny nose, sinus pain (sinusitis)
- Mouth sores or tongue ulcers (oral mucositis)
- Elevated bilirubin levels in blood
Uncommon
Affects up to 1 in 100 patients
- Pancytopenia (reduced counts of all blood cell types simultaneously)
- Cardiomyopathy (disease of the heart muscle)
- Sweet syndrome (acute febrile neutrophilic dermatosis) – red, raised painful patches on skin, fever, elevated white blood cells
Not Known
Frequency cannot be estimated from available data
- Interstitial lung disease (inflammation of lung tissue)
- Differentiation syndrome – a serious immune reaction
- Enterocolitis, colitis, and cecal inflammation (inflammation of the intestines) – symptoms include abdominal pain, bloating, or diarrhea. Enterocolitis can lead to sepsis and may be life-threatening.
Managing Side Effects
Most side effects of DACOGEN are manageable with appropriate supportive care. Myelosuppression is expected and is an integral part of the drug's mechanism of action – by suppressing the abnormal leukemia cells in the bone marrow, decitabine creates space for normal blood cell production to resume. During the initial cycles, you may need blood transfusions (for anemia or low platelets) and possibly growth factor support (such as G-CSF) to help your white blood cell count recover. Prophylactic antibiotics or antifungal medications may be prescribed to reduce infection risk during periods of severe neutropenia.
Gastrointestinal side effects such as nausea, vomiting, and diarrhea can typically be managed with anti-emetic (anti-nausea) medications and adequate hydration. Your healthcare team will provide specific guidance on managing these symptoms. Fever should always be taken seriously in patients receiving DACOGEN, as it may indicate a potentially dangerous infection requiring urgent antibiotic treatment.
It is important to report all side effects to your healthcare team, even if they seem minor. Early reporting allows your medical team to intervene promptly and adjust your treatment if necessary. Never attempt to manage serious symptoms such as high fever, severe bleeding, or breathing difficulties on your own – seek immediate medical attention.
Reporting Side Effects
Reporting suspected adverse reactions after the drug has been authorized is important for ongoing monitoring of the medicine's benefit-risk balance. Healthcare professionals and patients are encouraged to report any suspected side effects to their national pharmacovigilance authority, such as the FDA MedWatch program in the United States, the Yellow Card scheme in the United Kingdom, or the EMA EudraVigilance system in Europe.
How Should You Store DACOGEN?
The storage and handling of DACOGEN is the responsibility of your doctor, nurse, or hospital pharmacist. As a patient, you will not typically need to store this medication yourself, but understanding the storage requirements helps ensure you receive a properly prepared product.
- Unopened vials: Store at or below 25°C (77°F). Keep out of the sight and reach of children.
- Shelf life: Do not use after the expiration date stated on the carton and vial label (marked EXP). The expiration date refers to the last day of that month.
- After reconstitution: The concentrated solution must be further diluted with cold infusion fluid within 15 minutes of reconstitution.
- Diluted solution: The final prepared infusion solution can be stored refrigerated at 2–8°C for up to 3 hours, followed by up to 1 hour at room temperature (20–25°C) before administration.
- Disposal: Any unused DACOGEN solution must be disposed of according to local regulations for cytotoxic waste. Single-use vials only – any remaining solution should be discarded.
These strict storage conditions ensure the chemical stability and sterility of the prepared solution. The healthcare professionals administering your DACOGEN infusion are trained to follow these guidelines precisely, ensuring that you receive a safe and effective product at every treatment session.
What Does DACOGEN Contain?
Active Ingredient
The active substance in DACOGEN is decitabine (also known as 5-aza-2'-deoxycytidine). Each glass vial contains 50 mg of decitabine as a powder for concentrate for solution for infusion. When reconstituted with 10 ml of water for injections, the resulting concentrate contains 5 mg/ml of decitabine. This concentrate is then further diluted before administration to achieve a final infusion concentration of 0.15 to 1.0 mg/ml.
Inactive Ingredients (Excipients)
- Potassium dihydrogen phosphate (E340)
- Sodium hydroxide (E524) – for pH adjustment
- Hydrochloric acid – for pH adjustment
Appearance
DACOGEN is a white to almost white powder supplied in a 20 ml glass vial. Each package contains 1 vial. After reconstitution with water for injections, the solution has a pH between 6.7 and 7.3. The reconstituted concentrate should appear clear and free of visible particles before further dilution and administration.
Manufacturer
DACOGEN is manufactured by Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse, Belgium. The marketing authorization holder is Janssen-Cilag International NV, located at the same address. DACOGEN was first approved for use in the European Union in September 2012 and has since been authorized in multiple countries worldwide for the treatment of AML in adult patients not eligible for standard induction chemotherapy.
Frequently Asked Questions About DACOGEN
DACOGEN (decitabine) is a hypomethylating agent used to treat adults newly diagnosed with acute myeloid leukemia (AML) who are not candidates for standard intensive induction chemotherapy. This typically includes elderly patients (65 years and older) and those with significant comorbidities that make aggressive chemotherapy too risky. DACOGEN works by reversing abnormal DNA methylation in leukemia cells, helping to restore normal blood cell production.
DACOGEN is given as an intravenous (IV) infusion over 1 hour by a healthcare professional in a hospital or clinic. The dose of 20 mg/m² is administered once daily for 5 consecutive days, followed by a 23-day rest period. This 4-week cycle is repeated for a minimum of 4 cycles. Treatment may continue for many months or longer if the patient is benefiting. The epigenetic mechanism requires multiple cycles to achieve full effect.
The most serious side effects of DACOGEN include severe myelosuppression (dangerously low blood cell counts) which can lead to life-threatening infections and bleeding, pneumonia, sepsis (bloodstream infection), intracranial hemorrhage, and differentiation syndrome. Enterocolitis (intestinal inflammation) can also occur and may be life-threatening. Any high fever, severe bleeding, breathing difficulties, or sudden neurological symptoms should prompt immediate medical attention.
DACOGEN works through an epigenetic mechanism that takes time to produce clinical effects. Unlike traditional chemotherapy that may show results quickly, DACOGEN typically requires a minimum of 4 treatment cycles (approximately 4 months) before a meaningful response can be assessed. Some patients may not achieve their best response until after 6 or more cycles. It is important not to discontinue treatment prematurely, as early cycles may show worsening blood counts before improvement occurs.
DACOGEN is not typically considered a curative treatment for AML. It is used to control the disease, improve blood counts, reduce the need for transfusions, and extend survival in patients who cannot receive intensive curative-intent chemotherapy. Some patients achieve complete remission with DACOGEN, but the goal of treatment is often disease control and quality of life improvement rather than cure. Your doctor will discuss realistic treatment goals and expectations with you based on your individual situation.
Differentiation syndrome is a potentially serious immune reaction that can occur when leukemia cells rapidly mature in response to DACOGEN treatment. Symptoms include unexplained fever, cough, breathing difficulties, rash, decreased urine output, low blood pressure, swelling in the arms or legs, and rapid weight gain. While the exact frequency is not known, it is considered uncommon. If recognized early, differentiation syndrome can be effectively treated with corticosteroids and supportive care. Report any of these symptoms to your healthcare team immediately.
References
- European Medicines Agency (EMA). DACOGEN (decitabine) – Summary of Product Characteristics. Last updated 2024. Available from: EMA EPAR.
- U.S. Food and Drug Administration (FDA). DACOGEN (decitabine) Prescribing Information. Revised 2024. Available from: FDA Drug Label.
- Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia (DACO-016). J Clin Oncol. 2012;30(21):2670–2677. doi:10.1200/JCO.2011.38.9429.
- Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377. doi:10.1182/blood.2022016867.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 1.2025.
- DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971.
- Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562–569. doi:10.1200/JCO.2009.23.8329.
- Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103(5):1635–1640. doi:10.1182/blood-2003-03-0687.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- Krug U, Röllig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010;376(9757):2000–2008. doi:10.1016/S0140-6736(10)62105-8.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in hematology, oncology, and clinical pharmacology.
Medical Content
iMedic Hematology/Oncology Editorial Team – specialist physicians with clinical experience in leukemia treatment and epigenetic therapies
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, NCCN, and ELN guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics, and medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.